PI
KLRS

PFG Investments’s Kalaris Therapeutics KLRS Stock Holding History

PFG Investments’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-696
Closed -$6.72K – 1108
2024
Q4 		$6.72K Hold
696
– – ﹤0.01% 1024
2024
Q3 		$12.9K Sell
696
-130
-16% -$2.27K ﹤0.01% 1006
2024
Q2 		$13.7K Hold
826
– – ﹤0.01% 928
2024
Q1 		$14.3K Sell
826
-22
-3% -$359 ﹤0.01% 1028
2023
Q4 		$13.3K Buy
+848
New +$33.4K ﹤0.01% 482

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PFG Investments's KLRS Position: Q1 2025 in Review

PFG Investments sold out of Kalaris Therapeutics (KLRS) in Q1 2025, closing a stake of 696 shares — an estimated $6.72K sold.

PFG Investments first reported a position in KLRS in Q4 2023 and held it in 5 quarters. The position peaked at $14.3K in Q1 2024. 32 funds tracked by Wall St. Rank hold KLRS as of Q1 2025.

  • PFG Investments reported no remaining Kalaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • PFG Investments sold 696 Kalaris Therapeutics shares in Q1 2025, an estimated $6.72K.
  • PFG Investments first reported a position in Kalaris Therapeutics in Q4 2023 and held it in 5 quarters.
  • PFG Investments's Kalaris Therapeutics position peaked at $14.3K in Q1 2024.
  • 32 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2025.

Based on PFG Investments's 13F filing for Q1 2025, filed 22 Apr 2025.